58% of all blood cancer deaths are caused by the hardest to treat cancers.
We believe it’s possible to achieve significant shifts in survival, by making sure that all patients have access to the right treatment or drug at the right time.
That’s why we need to launch a major appeal to raise £25 million. This transformational investment in research, focussed across three programmes, will accelerate progress towards our goal of radical improvements in outcomes for these patients.
The £25 million we raise will be split across three £8 million blood cancer research projects – including innovative clinical trials focused on blood cancer that have never been seen before in the UK. We’ll also invest in vital services for patients, such as our Clinical Trials Support Service, helping to guide more patients towards the clinical trial that’s right for them – whilst supporting them through the process.
£25 million. 3 Groundbreaking research projects.
£8m to study the least survivable myeloid cancers.
£8m to research myeloma.
£8m to target the hardest to treat lymphomas.
£1m for our Clinical Trials Support Service.
Your impact
It’s an exciting time for blood cancer research, with significant breakthroughs ahead of us. Being part of the Board will have a huge impact, including:
- Funding 3 groundbreaking research projects for the hardest to treat blood cancers
- Discovering new drug combinations and therapies for patients who have run out of options
- Faster progress to discover new treatments by using adaptable, dynamic multi-arm, multi-stage studies in our clinical trials; moving, changing and developing treatments as trials progress
- Real-time impact for patients by giving access to new clinical trials and our Clinical Trials Support Service
- Widening the eligibility for clinical trials, so that more people, from all ages, stages and groups will be able to take part
- Creating change in NHS Practice for blood cancer patients
- Providing hope to blood cancer patients and increase the survival rates for the most deadly blood cancers.